文献速递外周动脉疾病

在因慢性肢体威胁性缺血接受初次旁路或球囊扩张伴或不伴支架植入的患者中验证BEST-CLI

Validation of BEST-CLI among patients undergoing primary bypass or angioplasty with or without stenting for chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2025-01-16

本研究回顾性分析2005至2022年在本中心因慢性肢体威胁性缺血(CLTI)首次接受下肢血运重建的患者,采用倾向性评分匹配模拟BEST-CLI标准。结果:使用单段大隐静脉(ssGSV)行旁路术者,7年大再次干预和MALE/死亡均显著低于血管内治疗组;无合适ssGSV者两组无显著差异。结论与BEST-CLI一致,提示其可推广性。

要点

  • 使用ssGSV行旁路术者7年大再次干预11% vs 血管内治疗24%(P=.001),MALE/死亡72% vs 78%(P=.03)。
  • 无合适ssGSV行旁路术者7年大再次干预25% vs 血管内治疗24%(P=.92),MALE/死亡82% vs 80%(P=.31)。
  • 两队列在完全伤口愈合、大截肢和截肢/死亡方面均无显著差异。

核心结论

  • 使用ssGSV行血运重建的患者,其大再次干预和MALE/死亡发生率显著低于血管内治疗者;无合适ssGSV行血运重建的患者未见类似结果。

研究设计与样本

  • 回顾性分析2005至2022年在本中心因CLTI首次接受下肢血运重建的所有患者。
  • 采用一对一倾向性评分匹配以模拟BEST-CLI;队列1为ssGSV旁路术对比PTA/S,队列2为非ssGSV旁路术对比PTA/S。
  • 共1946条患肢接受首次干预,其中765条行旁路术、1181条行PTA/S;匹配后队列1共862条(431条旁路术和431条PTA/S),队列2共274条(137条旁路术和137条PTA/S)。
  • 两队列中位随访均为2.7年。

主要发现

  • 队列1中,ssGSV旁路术组7年大再次干预11% vs PTA/S组24%(P=.001),MALE/死亡72% vs 78%(P=.03),均显著低于PTA/S组。
  • 队列1中,上述校正事件分别降低53%(HR 0.47;95%CI 0.30-0.74)和28%(HR 0.82;95%CI 0.69-0.98)。
  • 队列2中,7年大再次干预25% vs 24%(P=.92),MALE/死亡82% vs 80%(P=.31),均无显著差异。
  • 两队列在6个月完全伤口愈合(队列1:47% vs 40%,P=.32;队列2:40% vs 38%,P=.12)、7年大截肢(队列1:15% vs 15%,P=.89;队列2:35% vs 25%,P=.86)和7年截肢/死亡(队列1:70% vs 66%,P=.99;队列2:78% vs 76%,P=.45)方面均无显著差异。

临床怎么用

  • 作者认为,这些发现与BEST-CLI所示结果一致,提示其可推广性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: BEST-CLI established the superiority of single-segment great saphenous vein (ssGSV) conduits for revascularization in patients with chronic limb-threatening ischemia (CLTI); however, the generalizability of these data is unknown. Thus, we aimed to validate the long-term results of open surgical bypass (BPG) vs percutaneous transluminal angioplasty with or without stenting (PTA/S) using the BEST-CLI inclusion and randomization criteria. METHODS: All patients undergoing a first-time lower extremity revascularization for CLTI at our institution from 2005 to 2022 were retrospectively reviewed. To approximate BEST-CLI, one-to-one propensity score matching was used. Cohort 1 included BPG with ssGSV vs PTA/S; Cohort 2 included BPG without ssGSV vs PTA/S. Primary outcomes included wound healing, major amputation, major reintervention, major amputation/death (amputation/death), and major adverse limb events (MALE) or death (MALE/death) and were evaluated using Kaplan-Meier estimates and log-rank tests. RESULTS: Of 1946 limbs undergoing a first-time intervention for CLTI between 2005 and 2022, 765 underwent BPG and 1181 underwent PTA/S. After matching, 862 fit Cohort 1 (431 BPG and 431 PTA/S), and 274 fit Cohort 2 (137 BPG and 137 PTA/S). Both cohorts exhibited a median follow-up of 2.7 years. In Cohort 1, major reintervention and MALE/death were both noted to be significantly lower following ssGSV BPG, as compared with PTA/S (at 7 years: 11% vs 24%; P = .001 and 72% vs 78%; P = .03, respectively). These findings correlated with a 53% and 28% reduction in the aforementioned adjusted events (hazard ratio, 0.47; 95% confidence interval, 0.30-0.74 and hazard ratio, 0.82; 95% confidence interval, 0.69-0.98, respectively). These significant differences in major reintervention and MALE/death were not noted in Cohort 2 (at 7 years: 25% vs 24%; P = .92 and 82% vs 80%; P = .31, respectively). Further, neither cohort demonstrated significant differences in complete wound healing (at 6 months, Cohort 1: 47% vs 40%; P = .32; Cohort 2: 40% vs 38%; P = .12), major amputation (at 7 years: Cohort 1: 15% vs 15%; P = .89; Cohort 2: 35% vs 25%; P = .86), or amputation/death (at 7 years, Cohort 1: 70% vs 66%; P = .99; Cohort 2: 78% vs 76%; P = .45). CONCLUSIONS: Patients undergoing revascularization using ssGSV demonstrate significantly lower rates of major reintervention and MALE/death compared with those undergoing endovascular interventions for CLTI. However, similar outcomes are not seen among patients undergoing revascularization without a suitable ssGSV. These findings correlate with those demonstrated in BEST-CLI, suggesting generalizability.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Darling JD, Guetter CR, Park J, et al. Validation of BEST-CLI among patients undergoing primary bypass or angioplasty with or without stenting for chronic limb-threatening ischemia. J Vasc Surg. 2025. PMID: 39826656. doi:10.1016/j.jvs.2025.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。